Pralsetinib in the treatment of pleomorphic xanthoastrocytoma with RET‑activated: A case report
Year: 2026
Type: article
Study design: Case Report
Abstract: Rearranged during transfection (RET)‑activated gliomas are exceptionally rare and associated with a poor prognosis, and there are no established effective therapies. Clinical data on RET inhibitors are predominantly derived from solid tumors such as non‑small cell lung cancer and medullary thyroid carcinoma, with data for central nervous system tumors being scarce. The present report describes a case of pleomorphic xanthoastrocytoma with RET activation that progressed following the Stupp regimen but subsequently exhibited a favorable response to pralsetinib, teniposide and bevacizumab. The tumor area decreased from 4.84 cm2 before treatment to 1.92 cm2 (calculated based on the longest and maximum perpendicular diameters).
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7236591826
